Reversible inhibition of sperm under guidance as an intratubular and reversible contraception in female rats: An experimental study


Background: Reversible inhibition of sperm under guidance (“RISUG®”) is a promising intravasal male contraceptive.

Objective: An exploratory study was conducted with a concept of non-invasive, transcervical, single-intervention and reversible contraception using RISUG® in females.

Materials and Methods: In this experimental study, 60 adult Wistar albino female rats weighing 150-155 g, 3-4 months old were divided into four groups: group I: sham-operated control; group II: tubal occlusion with RISUG for 90 days; group III: tubal occlusion with RISUG® for 90 days and reversal with dimethyl sulphoxide and group IV: tubal occlusion with RISUG® for 90 days and reversal with 5% NaHCO3. Animals were subjected to bilateral fallopian tube occlusion with RISUG® and reversal with DMSO and NaHCO3. The estrous cycle, fertility and histology of fallopian tube were evaluated.

Results: Group I showed 100% fertility during all mating schedules. Animals of experimental groups indicated positive mating, but 0% fertility was evident following 30, 60, and 90 days of tubal occlusion. However, after reversal, fertility steadily increased to normalcy in groups III (50% at 45 days, 80% at 105 days, 100% at 150 and 195 days) and IV (70% at 45 and 105 days, 100% at 150 and 195 days) animals. Group II illustrated disorganized inner cell linings and eosinated RISUG® implant-filled lumen. Reversal groups (III and IV) revealed complete restoration of cellular histo-architecture. Regular estrous cycle was noticed in all experimental groups.

Conclusion: RISUG® is suitable for single intervention, intratubular, reversible contraception in female rats.

Key words: Contraception, Fallopian tube, Tubal occlusion, RISUG®, Reversible.

[1] Ceballos G, Ehrlich PR, Dirzo R. Biological annihilation via the ongoing sixth mass extinction signaled by vertebrate population losses and declines. Proc Natl Acad Sci USA 2017; 114: E6089–E6096.

[2] Bavel JV. The world population explosion: causes, backgrounds and projections for the future. Facts Views Vis Obgyn 2013; 5: 281–291.

[3] Jain R, Muralidhar S. Contraceptive methods: Needs, options and utilization. J Obstet Gynecol India 2011; 61: 626–634.

[4] Jokinen E, Heino A, Karipohja T, Gissler M, Hurskainen R. Safety and effectiveness of female tubal sterilisation by hysteroscopy, laparoscopy or laparotomy: a register based study. An Int J of Obstet Gynaecol 2017; 124: 1851–1857.

[5] Sharma RS, Rajanna A, Singh BK, Mathur AK, Mukherjee AK. Current Status of development of RISUG: An intravasal injectable male contraceptive. In: Sharma RS, Rajanna A, Rajalakshmi M (Eds.). Recent advances and challenges in Reproductive Health Research. New Delhi: Indian Council of Medical Research; 2008. pp: 135–149.

[6] Lohiya NK, Manivannan B, Mishra PK, Pathak N, Balasubramanian SPA. Intravasal contraception with styrene maleic anhydride and its non-invasive reversal in langur monkeys (Presbytis entellus entellus). Contraception 1998; 58: 119–128.

[7] Lohiya NK, Suthar R, Khandelwal A, Goyal S, Ansari AS, Manivannan B. Sperm characteristics and teratology in rats following vas occlusion with RISUG and its reversal. Int J Androl 2010; 33: e198–e206.

[8] Lohiya NK, Alam I, Hussain M, Khan SR, Ansari AS. RISUG: An intravasal injectable male contraceptive. Indian J Med Res 2014; 140 (Suppl.): 63–72.

[9] Ansari AS, Alam I, Hussain M, Khan SR, Lohiya NK. Evaluation of genotoxicity in leukocytes and testis following intra-vasal contraception with RISUG and its reversal by DMSO and NaHCO3 in Wistar albino rats. Reprod Toxicol 2013; 36: 53–59.

[10] Ansari AS, Hussain M, Khan SR, Lohiya NK. Relative suitability of DMSO and NaHCO3 for reversal of RISUG® induced long-term contraception. Andrology 2016; 4: 306–313.

[11] Ansari AS, Badar A, Balasubramanian K, Lohiya NK. Contraception with RISUG® and functional reversal through DMSO and NaHCO3 in male rabbits. Asian J Androl 2017; 19: 389–395.

[12] Lohiya NK, Manivannan B, Mishra PK, Sriram S, Bhande SS, Panneerdoss S. Preclinical evaluation for non-invasive reversal following long-term vas occlusion with styrene maleic anhydride in langur monkeys. Contraception 2005; 71: 214–226.

[13] Chaube SK, Misro MM. Effect of styrene maleic anhydride (SMA) on viability and integrity of isolated oocytes in vitro. Contraception 2002; 66: 469–472.

[14] Jha RK, Jha PK, Rana SV, Guha SK. Spermicidal action of styrene maleic anhydride polyelectrolyte in combination with magnetic and electrically conductive particle. Int J Pharmacol 2009; 5: 1–12.

[15] Guha SK. Contraceptive for use by a male. US: Patent; 54880705; 1996.

[16] Goldman JM, Murr AS, Cooper RL. The rodent estrous cycle: characterization of vaginal cytology and its utility in toxicological studies. Birth Defects Research 2007; 80: 84–97.

[17] CPCSEA guidelines. Guidelines on the regulation of scientific experiments on animals. Available at: CPCSEA_inner_page.pdf.

[18] Lin ChM, Ku YL, Cheng YT, Giin NY, Ou YCh, Lee MCh, et al. An uncommon spontaneous right distal tubal pregnancy post bilateral laparoscopic sterilization. A case report. Medicine 2019; 98: e14193–e14195.

[19] FDA medical devices. FDA activities: Essure. page last updated 04/09/2018. Available at: ents/fda-restricts-sale-and-distribution-essure-protect-w omen-and-require-patients-receive-risk.

[20] Hologic. Instructions for use and radiofrequency (RF) generator operator are manual. Available at: www.adiana. com/pdf/info/adiana-patient-information-booklet.pdf.

[21] Frietze G, Leyser-Whalen O, Rahman M, Rouhani M, Berenson AB. A meta-analysis of bilateral essure® procedural placement success rates on first attempt. J Gynecol Surg 2015; 31: 308–317.

[22] Mao J, Pfeifer S, Schlegel P, Sedrakyan A. Safety and efficacy of hysteroscopic sterilization compared with laparoscopic sterilization: an observational cohort study. Br Med J 2015; 31: 351.

[23] Clarke JJ, Sokal DC, Cancel AM, Campen DB, Gudi R, Wagner VO, et al. Re-evaluation of the mutagenic potential of quinacrine dihydrochloride dihydrate. Mutat Res 2001; 494: 41–53.

[24] Lippes J. Quinacrine sterilization (QS): Time for reconsideration. Contraception 2015; 92: 91–95.

[25] Jensen JT, Hanna C, Yao Sh, Micks E, Edelman A, Holden L, et al. Blockade of tubal patency following transcervical administration of polidocanol foam: initial studies in rhesus macaques. Contraception 2014; 89: 540–549.

[26] Jensen JT, Hanna C, Yao Sh, Bauer C, Morgan TK, Slayden OD. Characterization of tubal occlusion after transcervical polidocanol foam (PF) infusion in baboons. Contraception 2015; 92: 96–102.

[27] Yao S, Hanna C, Slayden OD, Jensen J. An ex vivo model for assessing acute effects of transcervical polidocanol foam in the macaque fallopian tube. Fertil Steril 2016; 106: e113.

[28] Briceag I, Costache A, Purcarea VL, Cergan R, Dumitru M, Briceag I, et al. Fallopian tubes: Literature review of anatomy and etiology in female infertility. J Med Life 2015; 8: 129–131.

[29] Eggert-Kruse W, Kohler A, Rohr G, Runnebaum B. The pH as an important determinant of sperm mucus interaction. Fertil Steril 1993; 59: 617–628.